Table 1 Participant characteristics (n = 800)
| Â | MHA status | p | |
|---|---|---|---|
Voluntary n (%) | Involuntary n (%) | ||
Total cohort population | 507 (63.4) | 293 (36.6) | Â |
Gender (male) | 284 (56.0) | 175 (59.7) | 0.3 |
Age (years), mean (SD) | 38.1 (12.1) | 38.8 (11.9) | 0.6 |
Country of birth | Â | Â | 0.03 |
 Australia | 397 (78.3) | 206 (70.3) |  |
 Asia | 45 (8.9) | 26 (8.9) |  |
 Pacifica | 25 (4.9) | 23 (7.8) |  |
 Other (Africa, Americas, Europe) | 40 (7.9) | 38 (13.0) |  |
Cohort |  |  | < 0.001 |
 1 | 155 (77.5) | 45 (22.5) |  |
 2 | 130 (65.0) | 70 (35.0) |  |
 3 | 128 (64.0) | 72 (36.0) |  |
 4 | 94 (47.0) | 106 (53.0) |  |
Length of admission (days), median (IQR) | 7 (10) | 15 (16) | < 0.001 |
Admissions (last 12 months) |  |  | 0.003 |
 None | 122 (24.0) | 88 (30.0) |  |
 One | 229 (45.2) | 93 (31.7) |  |
 Two | 83 (16.4) | 58 (19.8) |  |
  ≥ Three | 73 (14.4) | 54 (18.5) |  |
Primary diagnosis |  |  | < 0.001 |
 Schizophrenia | 102 (20.1) | 157 (53.6) |  |
 Bipolar disorder | 41 (8.1) | 52 (17.8) |  |
 Other psychotic disorder | 40 (7.9) | 27 (9.2) |  |
 Other mood disorder | 174 (34.3) | 25 (8.5) |  |
 Otherb | 150 (29.6) | 32 (10.9) |  |
Substance use disorder | 189 (37.3) | 105 (35.8) | 0.7 |
ECT treatment during admission | 9 (1.8) | 26 (8.9) | < 0.001 |
Previous/current clozapine treatment | 24 (4.7) | 37 (12.6) | < 0.001 |